Cancer Med: the immune checkpoint gene VSIR predicts prognosis in patients with acute myeloid leukemia and myelodysplastic syndromes

Immune checkpoint proteins play a key role in the immune response to cancer and have been targeted for immune checkpoint blocking therapy
.
V-domain Ig inhibition of T cell activation (VSIR) is one of these immune checkpoint genes that has been extensively studied
in recent years due to its conflicting roles in cancer immunity.
Specifically, the prognostic value of VSIR in acute myeloid leukemia (AML) is controversial
.

In patient tumor samples and cancer cell lines, a team found that VSIR had the highest AML expression in all cancer types and the highest expression
in AML in all other immune checkpoint genes.
Survival analysis showed that even in established AML subgroups (e.
g.
, FAB subtypes), AML patients with higher VSIR expression had significantly shorter survival than those with
lower expression.
Importantly, VSIR expression predicts progression to AML in patients with myelodysplastic syndrome (MDS), suggesting a potential role
in the early stages of AML development and progression.
In addition to AML, VSIR has shown prognostic value for other cancer types, including multiple myeloma and mesothelioma
.

Figure 1: VSIR is most expressed in AML and has a good
prognosis.

Figure 2: Validating the prognostic value
of VSIR in GSE14468.

Figure 3: Association of VSIR with genomic landscape
.

Figure 4: VSIR expression in single cells associated with leukemia

Figure 5: Prognostic value
of VSIR in other blood cancer types.

Original source:

Yao K, Zhou E, Schaafsma E, Zhang B, Cheng C.
Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes.
Cancer Med.
2022 Nov 16.
doi: 10.
1002/cam4.
5409.
Epub ahead of print.
PMID: 36394080.